Adzenys XR-ODT

Neos Therapeutics Inc (NASDAQ: NEOS) shares began tumbling on June 20, despite announcing late on June 19 that the FDA approved its Cotempla XR-ODT, a methylphenidate extended-release orally disintegrating tablet for treating attention-deficit/hyperactivity disorder in patients aged 6–17...